Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

This is something that has been rattling away

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Insync_2000 Member Profile
 
Followed By 1
Posts 144
Boards Moderated 0
Alias Born 12/06/08
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 5:29:34 PM
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc. GlobeNewswire Inc. - 6/16/2020 4:30:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post ... GlobeNewswire Inc. - 6/15/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/1/2020 4:15:58 PM
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education GlobeNewswire Inc. - 6/1/2020 7:00:10 AM
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19 GlobeNewswire Inc. - 5/21/2020 4:05:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardia... GlobeNewswire Inc. - 5/14/2020 2:50:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2020 5:19:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/30/2020 6:39:17 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2020 6:32:26 AM
Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 4/30/2020 5:00:10 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/29/2020 4:12:49 PM
Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020 GlobeNewswire Inc. - 4/28/2020 7:00:10 AM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/13/2020 4:37:32 PM
Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update GlobeNewswire Inc. - 4/8/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/31/2020 9:23:01 AM
Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific ... GlobeNewswire Inc. - 3/31/2020 7:00:10 AM
Amarin Comments on Ruling in VASCEPA® ANDA Litigation GlobeNewswire Inc. - 3/30/2020 6:25:32 PM
Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Ou... GlobeNewswire Inc. - 3/30/2020 11:45:10 AM
Pharmaceutical Firms Curtailing In-Person Sales Calls to Doctors Dow Jones News - 3/16/2020 2:29:00 PM
Eight Data Presentations Relevant to VASCEPA® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 3/16/2020 8:00:10 AM
Amarin Takes Proactive Steps to Support Public Health Priorities GlobeNewswire Inc. - 3/15/2020 1:56:22 PM
Insync_2000   Saturday, 05/23/20 10:56:57 AM
Re: None
Post # of 284509 
This is something that has been rattling away in the back of my mind for a while now. Why wouldn't Amarin start a subsidiary to market generic vascepa through in the USA, should their effort to protect their brand name patent fail on appeal.

Given that they are a one drug company that sells a relatively cheap drug, and that they already control supply, wouldn't it be a shoe in for them to be first in line should a pharmacist look for a generic version which in turn would make it less attractive for the generics to even enter the market.

Seems to me that they are holding all the cards and don't seem to know what to do with them.

They should be going after an ANDA right now through a subsidiary so that they are in position to protect their franchise should the appeal fail.

Should they prevail in their appeal, collapse the subsidiary and move on with marketing the brand name product. What could it possibly cost. Probably well worth it for peace of mind and to protect their market

Just a thought given that JT doesn't seem to have one.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist